No Relenza giveaway without our approval: Biota CEO
28 October, 2005 by Ruth BeranGlaxoSmithKline (GSK) would have to seek approval from Melbourne-based Biota Holdings (ASX:BTA) before the multinational pharmaceutical company could give away any licensing rights to the anti-flu drug Relenza, Biota's CEO Peter Molloy said today.
pSivida signs licensing deal in China
28 October, 2005 by Helen SchullerPerth-based bio-nanotech company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has signed a licence deal worth more than AUD$2.64 million with a US-based firm.
C3 treats first European patient with CellSpray
28 October, 2005 by Helen SchullerTissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.
BRC earns US marketing approval
28 October, 2005 by Helen SchullerThe Brain Resource Company (ASX:BRC) has been granted approval from the US FDA to market its methodology and standardised international human brain database.
Cracks appearing in GM moratoria
28 October, 2005 by Graeme O'NeillThe first cracks have appeared in the Australia-wide moratoria on genetically modified crops, with the decision of the Primary Industries Ministerial Council (PIMC) to adopt a threshold level of 0.9 per cent for adventitious presence of GM grain in conventional canola.
Biota raises $31m
27 October, 2005 by Ruth BeranMelbourne's Biota Holdings (ASX:BTA) has raised approximately $31 million from its share purchase plan (SPP) which closed early on October 12.
Agenix cuts COO position
27 October, 2005 by Ruth BeranBrad Calvin is to step down as chief operating officer of Agenix (ASX:AGX) today after the company decided not to renew his employment contract.
PacMab to raise $5m in IPO
27 October, 2005 by Helen SchullerSydney-based cancer drug development company PacMab has lodged a prospectus for an IPO to raise AUD$5 million to commercialise its treatment for a fatal blood cancer and potentially other blood disorders, with listing of its shares on the ASX expected in December this year.
AtCor Medical IPO closes early and oversubscribed
27 October, 2005 by Ruth BeranSydney-based devices company AtCor Medical has closed its initial public offering (IPO) early and oversubscribed.
Amrad changes name to Zenyth Therapeutics
27 October, 2005 by Ruth BeranMelbourne-based Amrad (ASX:AML) will now be known as Zenyth Therapeutics, following a vote at the company's AGM today.
Liability report addresses GM concerns
27 October, 2005 by Helen SchullerIndustry peak body AusBiotech has urged crop growers and marketers to throw their support behind GM technology, following the release of a report that found current legal, farming and commercial systems can adequately deal with issues that may arise from the use of the technology.
J&J exec names comms technology as medical driver
26 October, 2005 by Helen SchullerCommunication technology will be a key driver of medical innovation in the future, a senior Johnson & Johnson executive told a Sydney forum this week.
CathRx lists on ASX at a premium
26 October, 2005 by Helen SchullerSydney medical device company CathRx (ASX:CXD)has made a dream debut on the ASX - after opening at AUD$1.11, shares in the company have traded hands today at up to $1.35, a premium of 35 per cent.
Novogen encouraged by cancer drug trials
25 October, 2005 by Graeme O'NeillAustralian pharma Novogen has received further positive news from a US trial of its experimental cancer-resensitising agent phenoxodiol.
First operating revenues for Ventracor
25 October, 2005 by Ruth BeranSydney-based artificial heart company Ventracor (ASX:VCR) will report its first operating revenues of more than $300,000 in the first half of the 2006 financial year.
